Pulse Wave Analysis and Velocity in Patients With Chronic Renal Failure: a Cross-sectional Observational Study to Assess Association With Left Ventricular Hypertrophy, Uremic Toxins and Inflammation.

CHRONIC RENAL FAILURE Clinical Trial

Official title:

Pulse Wave Analysis and Velocity in Patients With Chronic Renal Failure: a Cross-sectional Observational Study to Assess Association With Left Ventricular Hypertrophy, Uremic Toxins and Inflammation.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01579032
• Other study ID #: ML2863
• Status: Completed
• Start date: January 2004
• Est. completion date: January 2012

Study information

• Verified date: October 2018
• Source: Universitaire Ziekenhuizen Leuven
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aims of the presented study are as follows:

1. To evaluate the endothelial function and arterial stiffness in a large cohort of prevalent CKD patients by means of non-invasive applantion tonometry.

2. To evaluate the association between the serum levels of the representatives of the various classes of uremic toxins and markers of endothelial function and arterial stiffness.

3. To evaluate the association between markers of inflammation and oxidative stress and markers of endothelial function and arterial stiffness.

4. To evaluate the association between echocardiographic parameters and markers of arterial stiffness

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: January 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age: 18-60

• Chronic kidney disease: according to the K-DOQI guidelines ( kidney damage = three months, as defined by structural or functional abnormalities of the kidney, with or without decreased GFR, manifest by either: pathological abnormalities; or markers of kidney damage, including damage in the composition of blood or urine test, or abnormalities in imaging tests; GFR< 60 ml/min/1.73m² for = three months, with or without kidney damage)

• Written informed consent

Exclusion Criteria:

• major illnesses( life expectancy of < 1 year)

• history of atrial fibrillation

• history of myocardial infarction, unstable angina, congestive heart failure, peripheral vascular diasease ,cerebrovascular disease, diabetes

(nonechogenic)

Related Conditions & MeSH terms

• Arterial Stiffness
• CHRONIC RENAL FAILURE
• Hypertrophy
• Hypertrophy, Left Ventricular
• Inflammation
• Kidney Failure, Chronic
• Left Ventricular Hypertrophy
• Renal Insufficiency
• Renal Insufficiency, Chronic

Locations

Country	Name	City	State
Belgium	University Hospitals	Leuven
Belgium	UZ Leuven	Leuven

Sponsors (1)

Lead Sponsor	Collaborator
Universitaire Ziekenhuizen Leuven

Country where clinical trial is conducted

Belgium,